Fc-based half-life extension of human FVIIa - a new player for hemophilia treatment?

被引：0
|
作者：
Margaritis, Paris [1 ]
机构：
[1] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
来源：
THROMBOSIS RESEARCH | 2015年 / 135卷 / 05期
关键词：
Hemophilia; Coagulation Factor VIIa; Half-life; Fc fusion; RECOMBINANT FACTOR VIIA; COAGULATION-FACTOR VIIA; ALBUMIN RVIIA-FP; PROPHYLAXIS; INHIBITORS; EFFICACY;
D O I：
10.1016/j.thromres.2015.02.030
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：775 / 776
页数：2
相关论文
共 50 条
  • [21] Facile and Efficient Chemoenzymatic Semisynthesis of Fc-Fusion Compounds for Half-Life Extension of Pharmaceutical Components
    Hirasawa, Shigeo
    Kitahara, Yoshiro
    Okamatsu, Yoriko
    Fujii, Tomohiro
    Nakayama, Akira
    Ueno, Satoko
    Ijichi, Chiori
    Futaki, Fumie
    Nakata, Kunio
    Taki, Masumi
    BIOCONJUGATE CHEMISTRY, 2019, 30 (09) : 2323 - 2331
  • [22] Extension of human GCSF serum half-life by the fusion of albumin binding domain
    Fatemeh Yadavar Nikravesh
    Samira Shirkhani
    Elham Bayat
    Yeganeh Talebkhan
    Esmat Mirabzadeh
    Masoumeh Sabzalinejad
    Hooman Aghamirza Moghim Aliabadi
    Leila Nematollahi
    Yalda Hosseinzadeh Ardakani
    Soroush Sardari
    Scientific Reports, 12
  • [23] Extension of human GCSF serum half-life by the fusion of albumin binding domain
    Nikravesh, Fatemeh Yadavar
    Shirkhani, Samira
    Bayat, Elham
    Talebkhan, Yeganeh
    Mirabzadeh, Esmat
    Sabzalinejad, Masoumeh
    Aliabadi, Hooman Aghamirza Moghim
    Nematollahi, Leila
    Ardakani, Yalda Hosseinzadeh
    Sardari, Soroush
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [24] Comment on "Enhanced Half-Life Recombinant Factor VIII Concentrates for Hemophilia A: Insights from Pivotal and Extension Studies"
    Horneff, Regina
    Bystricka, Linda
    Santagostino, Elena
    Lethagen, Stefan
    Casiano, Sandra
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2022, 48 (02): : 251 - 252
  • [25] Fusion of a procoagulant peptide to Fc improves its physical properties and prolongs its in vivo Half-life in Hemophilia A Mice
    Hong, Vu
    Zhang, Ming
    Liu, Lucy
    Van Der Flier, Arjan
    Liu, Zhan
    Rakhe, Swapnil
    Pierce, Glenn
    Mezo, Adam
    Peters, Robert T.
    Kulman, John
    HAEMOPHILIA, 2014, 20 : 120 - 120
  • [26] Extended half-life recombinant factor VIII treatment of hemophilia A in Brazil: an expert consensus statement
    Ozelo, Margareth Castro
    Antunes, Sandra Vallin
    Villaca, Paula Ribeiro
    Oliveira, Luciana Correa
    Pinto, Ieda Solange
    Lorenzato, Claudia Santos
    Prezotti, Alessandra Nunes Loureiro
    Picoli, Renato Mantelli
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2024, 46 (01) : 36 - 41
  • [27] Use of extended half-life rFVIII-Fc or rFIX-Fc in previously treated patients with hemophilia A or B. A single center experience
    Ruiz-Saez, A.
    Boadas, A.
    Echenagucia, M.
    HAEMOPHILIA, 2019, 25 : 50 - 51
  • [28] In Vivo Half-Life Extension of Peptide Derivatives Using Human Serum Albumin Binders
    Isidro-Llobet, Albert
    JOURNAL OF PEPTIDE SCIENCE, 2022, 28
  • [29] EXTENDED HALF-LIFE (EHL) RECOMBINANT FACTOR VIII (RFVIII) FOR THE TREATMENT OF HEMOPHILIA A IN ITALY: COST OF TREATMENT COMPARISON
    Demma, F.
    Di Martino, G.
    VALUE IN HEALTH, 2021, 24 : S203 - S203
  • [30] First human dose trial of subcutaneously administered recombinant activated factor VII (rFVIIa) to hemophilia A and B patients shows prolonged FVIIa half-life, and provides evidence of safety and tolerability
    Tiede, A.
    Lethagen, S.
    Friedrich, U.
    Stenmo, C.
    Allen, G.
    Giangrande, P.
    Goudemand, J.
    Hay, C.
    Holmstrom, M.
    Klamroth, R.
    Mckenzie, S.
    Miesbach, W.
    Negrier, C.
    Jimenez Yuste, V.
    Berntorp, E.
    HAEMOPHILIA, 2010, 16 : 68 - 68
12345